← Back to Search

Panel-based pharmacogenetic genotyping for Pharmacogenetic Testing

N/A

Waitlist Available

Led By Julio Duarte, PharmD, PhD

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will test whether panel-based pharmacogenetic testing leads to improved medication satisfaction for black and Latino patients.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Global Patient Treatment Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

Secondary outcome measures

Change in Patient Treatment Convenience Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

Change in Patient Treatment Effectiveness Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

Change in Patient Treatment Side Effect Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Panel-based pharmacogenetic genotypingExperimental Treatment1 Intervention

All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Panel-based pharmacogenetic genotyping

2021

N/A

~100

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Center for Advancing Translational Science (NCATS)NIH

99 Previous Clinical Trials

36,209 Total Patients Enrolled

University of FloridaLead Sponsor

1,340 Previous Clinical Trials

715,605 Total Patients Enrolled

1 Trials studying Pharmacogenetic Testing

492 Patients Enrolled for Pharmacogenetic Testing

National Center for Advancing Translational Sciences (NCATS)NIH

320 Previous Clinical Trials

401,630 Total Patients Enrolled

Media Library

Panel-based pharmacogenetic genotyping Clinical Trial Eligibility Overview. Trial Name: NCT04630093 — N/A

Pharmacogenetic Testing Research Study Groups: Panel-based pharmacogenetic genotyping

Pharmacogenetic Testing Clinical Trial 2023: Panel-based pharmacogenetic genotyping Highlights & Side Effects. Trial Name: NCT04630093 — N/A

Panel-based pharmacogenetic genotyping 2023 Treatment Timeline for Medical Study. Trial Name: NCT04630093 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the uppermost limit for participant enrollment in this clinical experiment?

"That is correct. Clinicaltrials.gov notes that this clinical trial, which was initially posted on May 13th 2021, is actively enrolling participants. This study requires 100 people to join from a single medical centre."

Answered by AI

Does my profile qualify me to participate in this investigation?

"This research trial is open to 100 individuals aged 18-99 with a recent pharmacogenetic test. Other inclusion requirements include: evidence of medication adjustment within the past 6 months, and self-identifying as either Black or Latinx."

Answered by AI

Are new participants still being accepted into this research?

"Affirmative. Clinicaltrials.gov confirms that recruitment is open for this medical project, which was first posted on May 13th 2021 and has since been revised on June 28th 2022. The trial seeks 100 applicants from one particular clinical site."

Answered by AI

Does the study accept participants younger than 80 years of age?

"In order to be accepted into this clinical trial, individuals must meet the age requirements. These are a minimum of 18 years and a maximum of 99 years old."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

2021. "Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04630093.